Entries by Rebecca Mercer

Recruiting: Ohlson Professor of Head and Neck Health Services Research, Department of Surgery, Cumming School of Medicine

Position Description The Department of Surgery, in the Cumming School of Medicine, University of Calgary, invite applications for a tenure track appointment as the Ohlson Professor of Head and Neck Health Services Research at the Assistant Professor level. This position includes a joint appointment in the Department of Community Health (more…)

New Release: Canadian Cancer Statistics: A 2022 special report on cancer prevalence

Developed in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada, with data provided by provincial and territorial cancer registries and analyses completed by Statistics Canada and the Canadian Partnership Against Cancer, this publication provides estimates of cancer prevalence by cancer type, sex, age, (more…)

Article: A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada

Regier, D.A., Pollard, S., McPhail, M. et al. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada. npj Precis. Onc. 6, 76 (2022). This important new article from CLEO is hot off the press (October 25, 2022) and was supported in part by ARCC, as well as Genome (more…)

Health Services Research Scientist – CancerCare Manitoba Research Institute

5-year Contingent Appointment – possibility of extension January 1, 2023 – Dec 31, 2027 Competition# 244-22 Applications accepted at  https://careers.wrha.mb.ca/job-invite/320410/ Job Summary: This is an exceptional opportunity for a qualified individual to contribute to the ongoing success of the Institute and the Institute’s strengths in cancer health services research with (more…)

Call for submissions – Current Oncology Special Issue on Real-World Evidence

Special Issue Information Dear Colleagues, Real-world evidence (RWE) has been a popular catchphrase for the last 10 years but could be considered the re-branding of clinical data that does not meet the typical randomized phase III study criteria often included in HTA submissions. Variations in patient populations (e.g., comorbidities, genetic (more…)